Antibody Purification via Small Molecule Affinity Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody purification methods, particularly affinity chromatography using protein A or protein G, face challenges such as high cost, instability, and contamination risks, leading to low yields and defective antibodies due to protein unfolding, misfolding, and aggregation.
Innovation Solution
The use of small molecule affinity chromatography, where a nucleotide binding site on antibodies is targeted by immobilized small molecules like indole-3-butyric acid, providing a stable and cost-effective alternative for antibody purification with reduced nonspecific interactions and increased column stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein A or protein G is used for affinity chromatography, then antibody purification is achieved, but cost increases and column stability decreases
Solution Approach 1:
The patent creates a simplified version of the natural antigen-antibody interaction by copying only the essential nucleotide-binding functionality. Instead of using complex recombinant proteins (Protein A/G), the invention uses small synthetic molecules that replicate the key binding capability, eliminating the need for expensive protein production while maintaining purification effectiveness
Solution Approach 2:
The patent employs inexpensive synthetic small molecules as affinity ligands instead of costly recombinant proteins. These small molecules can be easily synthesized and immobilized on chromatography matrices, providing a cost-effective alternative that maintains column stability and reduces manufacturing costs significantly
2Manufacturing precision
If multiple purification steps are used, then contaminants are removed, but antibody yield decreases and protein damage increases
Solution Approach 1:
The patent designs a universal small molecule affinity ligand that binds to a conserved nucleotide-binding site present on all antibodies regardless of their antigen specificity. This single universal ligand can purify any antibody type in one step, replacing multiple specialized purification steps and preventing protein damage that occurs through repeated processing
Solution Approach 2:
The patent extracts and isolates the essential purification function from complex multi-step processes. By identifying the conserved nucleotide-binding site as the key target, the invention extracts this specific binding interaction and builds a purification system around it, eliminating the need for multiple sequential steps and associated protein damage
3Reliability
If protein A or protein G is used, then affinity purification is achieved, but product contamination occurs through hydrolysis and peptide release
Solution Approach 1:
The patent copies only the essential antigen-binding functionality of Protein A/G without replicating their problematic proteolytic properties. The synthetic small molecules replicate the nucleotide-binding capability while eliminating the protein structures that cause hydrolysis and peptide release, thus maintaining selectivity without contamination
Solution Approach 2:
The patent converts the limitation of small molecules (lack of complex protein structure) into an advantage. By using simple synthetic molecules that bind specifically to the conserved nucleotide site, the invention eliminates the harmful proteolytic activity of Protein A/G while maintaining effective affinity purification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances antibody purity and recovery efficiency, reduces the need for expensive recombinant proteins, and extends column lifespan, enabling a single-step purification method suitable for various scales of antibody production.
Implementation Method 1
a nucleotide binding site on antibodies is targeted by immobilized small molecules like indole-3-butyric acid
Implementation Method 2
Antibody purification via affinity chromatography
Data Source
AI summary
Embodiments herein provide methods of purifying monoclonal and polyclonal antibodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid.